VALBIOTIS Releases Its 2020 Annual Results
2020 highlights and results
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects.
Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing Type 2 Diabetes risk factors.
New milestones achieved with TOTUM-070, a plant-based active substance for lowering LDL-cholesterol, a risk factor for cardiovascular disease.
€14.6m in cash as at December 31, 2020.
Post-balance sheet events and outlook
Important milestones are expected to be reached in the development of TOTUM-070 (reduction in blood LDL-cholesterol levels).